Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke
Conditions
Interventions
natalizumab
Placebo
Locations
50
United States
Research Site
San Diego, California, United States
Research Site
Gainesville, Florida, United States
Research Site
Kansas City, Kansas, United States
Research Site
Boston, Massachusetts, United States
Research Site
Golden Valley, Minnesota, United States
Research Site
St Louis, Missouri, United States
Start Date
January 1, 2014
Primary Completion Date
February 1, 2015
Completion Date
April 1, 2015
Last Updated
July 1, 2016
NCT07253181
NCT06990867
NCT07001267
NCT03153683
NCT07371624
NCT05847699
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions